RSV Vaccine Safety

Institutional safety information on respiratory syncytial virus (RSV) vaccines. Clinical data for Arexvy and Abrysvo, maternal immunization, and surveillance metadata.

Clinical Overview

Professional summary

Respiratory Syncytial Virus (RSV) is a prevalent respiratory pathogen. While typically presenting with mild, upper-respiratory symptoms in healthy adults, it is a primary driver of bronchiolitis and pneumonia in infants and severe lower respiratory tract disease (LRTD) in older adults.

The introduction of high-authority immunization modules in 2023 established a critical clinical defense, significantly reducing the incidence of life-threatening complications and acute hospitalizations within vulnerable cohorts.

Protects against Respiratory Syncytial Virus, a primary driver of lower respiratory tract disease (LRTD).

Advanced modules now available for geriatric cohorts (60+) and maternal protocols.

Clinical trials confirm high efficacy in preventing severe pathology and hospitalization.

Synchronized with 2026 active surveillance for durable seasonal protection.

Available Registry Modules

Vaccine modules

Geriatric Protocol (60+)

Approved 2023

Arexvy - GSK - Recombinant adjuvanted.
Abrysvo - Pfizer - Bivalent B subunit.

Maternal Protocol (Gestational)

Abrysvo (Pfizer)

Administered during weeks 32-36 of gestation to ensure passive neonatal immunity.

Analyze titration logic and seasonal administration windows on official nodes.

Eligibility & Schedules

Protocol triage

Geriatric Cohort (60+)

Single-dose seasonal protocol
Shared clinical decision-making required
Late summer / early fall administration

Gestational Protocol

Administer during weeks 32-36
Window: September through January
Transfers durable antibodies to infant

Contraindications

Anaphylaxis to previous RSV protocol dose
Acute moderate-to-severe illness state
Documented hypersensitivity to module components

Adverse Reaction Profile

Expected and critical events

Local Reactions

Injection site localized pain
Erythema (Redness)
Localized induration (Swelling)

Systemic Profile

Generalized fatigue
Myalgia (Muscle pain)
Cephalalgia (Headache)
Arthralgia (Joint stiffness)

Emergency Protocol

Adverse reactions from current RSV modules are typically mild, with a resolution mean of 48-72 hours.

Safety Metadata Analysis

Monitoring summary

2023

Registry Launch

60,000+

Trial Subjects

Global

Consensus Profile

Institutional Surveillance

Continuous active monitoring through VAERS and VSD has identified no unexpected clinical concerns. As 2023 modules, ongoing surveillance remains a clinical priority for long-term safety validation.

Verified Source: CDC / WHO

Last global review: September 1, 2025. Content verified by HCP Connect clinical editorial staff in alignment with 2026 safety protocols.